Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.73 |
| ▸ | RAB9A | P51151 | 7/20 | 0.73 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28230040 | 0.87 | NPC1 (0.66) | NPC1RAB9AMTORPTGS1MAPT | |
| SCHEMBL5091480 | 0.85 | NPC1 (0.77) | NPC1RAB9AMTORADORA3ADORA2A | |
| SCHEMBL6257291 | 0.85 | NPC1 (1.00) | NPC1RAB9AMTORADORA3ADORA2A | |
| SCHEMBL12204397 | 0.84 | NPC1 (1.00) | NPC1RAB9AMTORADORA3ADORA2A | |
| SCHEMBL4983597 | 0.83 | NPC1 (0.56) | NPC1RAB9A | |
| SCHEMBL15931641 | 0.82 | NPC1 (1.00) | NPC1RAB9AMTORADORA3ADORA2A | |
| SCHEMBL3775369 | 0.81 | KCNK3 (0.64) | NPC1RAB9APTGS1MAPTKMT2A | |
| SCHEMBL3767063 | 0.81 | RHOC (0.63) | NPC1RAB9AMTORPTGS1MAPT | |
| SCHEMBL31725147 | 0.80 | NPC1 (0.74) | NPC1RAB9AMTORADORA3ADORA2A | |
| SCHEMBL19616650 | 0.80 | NPC1 (0.74) | NPC1RAB9AMTORADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
| EP-1480954-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | NPC1 784/4885RAB9A 1477/4885MTOR 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.